Research digest: new horizons in heart failure therapy

When the concept of tackling type 2 diabetes with a drug that enhances urinary excretion of glucose was first mooted, many felt the idea was speculative; for years, doctors had been trying to lessen urinary glucose loss, not accentuate it. Undeterred, several companies pressed on with their development of sodium-glucose co-transporter-2 (SGLT2)...